News and Recommendations

This is an overview of our latest news.

  • 31/10/2018 PET improves diagnosis and treatment of Alzheimer’s Disease. New results of the Dutch ABIDE project associates PET scans to essential changes in diagnosis and treatment of amyloid plaques in the brain
  • 10/4/2018 Clinical collaboration announced between Telix Pharmaceuticals and Radboud University Medical Center. This highly interesting international collaboration lays the foundation for the completion of product development of 89Zr-Girentuximab
  • 10/4/2018 Review highlights newest advances in 89Zr chelation chemistry and development of DFO alternatives. An authorative overview of state-of-the art 89Zr chelators.
  • 21/10/2017 Meet the Team: Dr. Maria Vosjan. As Operations Manager at BV Cyclotron VU, Maria is member of the Management Team and responsible for all operational processes within the company. She is also involved in the implementation of new tracers and is ensuring a smooth transition to the new Imaging Center at the VUmc.
  • 12/10/2017 Meet us at EANM 2017 Vienna. We will be present at the 30th  Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria (oct. 21-25). See what we can do for you in relation to our products and services! Also, more information will be available about our brandnew laboratories and cyclotron facilities in the new Imaging Center in Amsterdam.
  • 7/9/2017 French and Dutch researchers jointly author an important new review on 89Zr-immunoPET. Researchers from the Radboud University Medical Center (Netherlands) and of the Université Bourgogne Franche-Comté (Dijon, France) have jointly authored a vast review covering the main medical applications of 89Zr-immunoPET as well as manufacturing aspects of 89Zr labeling for this end. The result: Labeling with 89Zr makes a lot of
    sense, improvements are welcome in the development of new chelators and bioconjugators.
  • 16/5/2017 The new state-of-the-art VUmc Imaging Center in Amsterdam. The construction work on our new fully integrated, state-of-the-art imaging site is making good progress. The new building will play a crucial role in the successful and efficient development of novel diagnostic and drug therapies.
  • 4/5/2017 PET with 89Zr-bevacizumab found promising to guide therapy in children with Diffuse Intrinsic Pontine Glioma. A team of investigators from the VU University Medical Center (Amsterdam, The Netherlands) verified that the monoclonal antibody (mAb) bevacizumab, labeled with 89Zr, is able to reach tumors in children with DIPG, by quantifying its uptake by the tumors via PET.
  • 2/2/2017 New technique uses 89Zr-radiolabelling of mixed leukocytes for PET imaging of inflammation
    . Newly published research has assessed the radiolabeling of WBCs with 89Zr or 64Cu and their advantages for PET imaging. Radiolabeling of WBCs was more efficient with ["[89zr]" not found]-loaded than with ["[64cu]" not found]-loaded CN. After 2 h, ["[89zr]" not found]-WBCs had an initial radioactivity loss of 28.4%, which was followed by a plateau as 89Zr remains stable in the cells. Differently, ["[64cu]" not found]-WBCs had a radioactivity loss of 85% already after 1 h, which increased to 96% after 3 h.
  • 18/1/2017 Alternative chelator for 89Zr-immuno-PET studies shows superior in vitro stability and in vivo performance. 89Zr-DFO*-trastuzumab shows to be far superior to 89Zr-DFO-trastuzumab. Recent research has introduced a bifunctional isothiocyanate variant of the octadentate chelator DFO* as an alternative for DFO in 89Zr-immuno-PET. The effects of both molecules, when conjugated with the monoclonal antibody trastuzumab, were compared in vitro (stability tests) and in vivo (biodistribution in N87 tumor-bearing mice and PET imaging).